Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Gains from Investment Securities (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Gains from Investment Securities for 17 consecutive years, with $5.0 million as the latest value for Q1 2026.

  • Quarterly Gains from Investment Securities rose 119.55% to $5.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Mar 2026, up 119.55% year-over-year, with the annual reading at $2.7 million for FY2025, 27.61% up from the prior year.
  • Gains from Investment Securities for Q1 2026 was $5.0 million at Achieve Life Sciences, up from $114000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $5.0 million in Q1 2026, with the low at -$114000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $878369.7, with a median of $390000.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities crashed 109.0% in 2022, then skyrocketed 405.65% in 2025.
  • Achieve Life Sciences' Gains from Investment Securities stood at -$47000.0 in 2022, then soared by 1460.64% to $639500.0 in 2023, then tumbled by 117.83% to -$114000.0 in 2024, then surged by 200.0% to $114000.0 in 2025, then skyrocketed by 4260.1% to $5.0 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Gains from Investment Securities are $5.0 million (Q1 2026), $114000.0 (Q4 2025), and $313500.0 (Q3 2025).